Antibodies that detect HEXB chain B can be used in several scientific applications, including Western Blot, Immunohistochemistry (Paraffin), Immunohistochemistry (Frozen), Immunocytochemistry and ELISA. This Rabbit polyclonal antibody targets HEXB chain B in Rat, Mouse and Human samples, and has been validated in experiments with 2 images featured in our data gallery.
Browse primary antibodies for WB, Flow, IHC, ICC/IF, ELISA, IP, and other applications. Antibodies with Advanced Verification data have been validated for specificity to ensure that the antibody binds to the antigen stated. If you cannot find the antibody you're looking for, contact us today to develop custom antibodies for specific targets, species and applications. Custom conjugation and purification services are available as well. View more
Hexosaminidase B is the beta subunit of the lysosomal enzyme beta-hexosaminidase that, together with the cofactor GM2 activator protein, catalyzes the degradation of the ganglioside GM2, and other molecules containing terminal N-acetyl hexosamines. Beta-hexosaminidase is composed of two subunits, alpha and beta, which are encoded by separate genes. Both beta-hexosaminidase alpha and beta subunits are members of family 20 of glycosyl hydrolases. Mutations in the alpha or beta subunit genes lead to an accumulation of GM2 ganglioside in neurons and neurodegenerative disorders termed the GM2 gangliosidoses. Beta subunit gene mutations lead to Sandhoff disease (GM2-gangliosidosis type II).
Beta-hexosaminidase subunit beta; Beta-hexosaminidase subunit beta chain A; Beta-hexosaminidase subunit beta chain B; Beta-N-acetylhexosaminidase subunit beta; Cervical cancer proto-oncogene 7 protein; epididymis luminal protein 248; epididymis secretory protein Li 111; HCC-7; hexosaminidase B (beta polypeptide); Hexosaminidase subunit B; N-acetyl-beta-glucosaminidase subunit beta
Searching for an antibody we don't offer? We make custom antibodies for specific targets, species and applications.
More than 18,000 custom antibodies created so far.Talk to a specialist now